Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, 21 March 2007

Touched By An Angel

Posted on 07:48 by Unknown

A few years ago, a polls suggested 79 percent of Americans believed in angels. I guess you can toss me in along with the rest.

What else can we conclude after reading a report put out by the Center for Venture Research at the University of New Hampshire? The center--which says it's been tracking angel investing since 1980--says Angels invested $25.6 billion in companies last year, a 10.8% increase from 2005.

This is a lot of money you're talking about. Any of the major data sources out there suggested venture capitalists--you know the ones with institutional capital?--put roughly $25 billion into companies last year, roughly the same amount.
These angels have some serious clout.

Who got the money? Well, most likely, someone you know. Health care companies--biotechnology, medical device and health care services companies--got a bulk of it or at least accounted for 39% of the 51,000 angel deals completed last year. The report doesn't give a breakdown of the capital committed.

That's nearly 20,000 investments (and $10 billion if the percentage could be applied to dollars, but that's probably not completely accurate. Could be more. Could be less. My guess is biotech, medical device deals get more than your average investment.)

So what's this all mean? For entrepreneurs, this is great news. There's a whole bunch of billions being invested in health care companies year after year, and start-ups appear to be getting a fair share.

But what's this mean for VCs? Well, take some solace in knowing there's someone out there funding the start-ups you no longer have the time nor patience to do yourselves. However, these folks are becoming a force, and they're going to be looking to get paid big time when their companies come to you looking for capital.
Email ThisBlogThis!Share to XShare to Facebook
Posted in financing, venture capital | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • EPO Relabeling: Its Not the Black Box, Its What FDA Says About the Black Box
    Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...
  • While You Were Settling
    Well, it was an interesting weekend: the writers' strike may have been settled, Obama swept (and won a Grammy), and there was an unusual...
  • Payday for RJ Kirk & New River
    Once again, ally turns to buy . Eager to land 100% of the two companies' profits from the soon-to-be-approved ADHD drug Vyvanse (former...
  • At JP Morgan, Stryker's Big Smile
    As he strode to the podium in during last week’s JP Morgan investor conference in San Francisco, Stryker Corp. CEO Steve MacMillan was all s...
  • Cracks in Crucible of Evidence-Based Medicine Create "Climate of Calamity"
    The real story emerging from this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, is not the news per ...
  • The Big Winner in the Vytorin Debacle? It Might be Lilly
    Steve Nissen's latest star turn , advising doctors everywhere to stop using Vytorin until there is better evidence it improves health ou...
  • The Wacky World of Generics: Protonix Edition
    Here is a headscratcher. Wyeth decided January 30 to launch an authorized generic version of its blockbuster proton pump inhibitor pantopraz...
  • Old Medicine in New Bottles
    Two excellent posts from the Wall Street Journal’s Health Blog and Pharmalot noted speculation from Credit Suisse on a Pfizer bid for Wyet...
  • Third Rock's a Charm
    It’s one of the oldest stories out there. Successful management team, a few years removed from running their own successful biopharmaceutica...
  • While You Were Staying Put
    It's always sunny in ... London? Lets kick off the weekend wrap-up by highlighting a trio of stories from The Times about incoming Glax...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ▼  March (13)
      • So Cimzia Will be Late, After All
      • Reporting on Exubera: an A-Buse
      • Has Sanofi-Aventis Lost its Friends in Government?
      • Touched By An Angel
      • Eternal Sunshine of the Spotless ... ooh cheese!
      • Schering-Plough Spends Big on Organon
      • When DDMAC Attacks
      • Amgen Sucks Up to Tony
      • Tekturna: looking for growth in antihypertensives
      • A Sleeper of a Deal
      • Sometimes the Bayer Gets You
      • AZ: Radical Re-think?
      • Can't Get VC? Try Charities
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile